Clinical trials: Ichthyosis
Netherton Syndrome
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older.
- Trial name
- NCT05856526
- Testing
- Spesolimab - solution for infusion, Spesolimab - solution for injection
- Where
- 28 sites in United States, Australia and 12 more
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Netherton Syndrome
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease.
- Trial name
- NCT05211830
- Testing
- SXR1096 cream
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 9 people
- Sponsor
- Sixera Pharma
Congenital Ichthyosis
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
The purpose of this study is to investigate the efficacy and safety of two concentrations of topically applied ointment formulation of isotretinoin called TMB-001 (0.05% and 0.1% isotretinoin) in subjects 9 years of age and older…
- Trial name
- NCT04154293
- Testing
- Isotretinoin, Vehicle
- Where
- 11 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- LEO Pharma
Autosomal Recessive Ichthyosis
Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).
- Trial name
- NCT05735158
- Testing
- KB105
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Krystal Biotech, Inc.
Ichthyosis Vulgaris
A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris
The objective of this study is to determine and compare the safety and efficacy of topical 146-9251 cream and vehicle cream applied twice daily for 6 weeks in subjects with moderate to severe ichthyosis vulgaris (IV).
- Trial name
- NCT03173547
- Testing
- 146-9251 cream, Vehicle cream
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Crown Laboratories, Inc.
Ichthyosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
- Trial name
- NCT04697056
- Testing
- Imsidolimab
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanda Pharmaceuticals
Congenital Ichthyosis
A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of cornification resulting from an abnormality of skin keratinization, such as scaling and thickening of the skin.
- Trial name
- NCT02864082
- Testing
- PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Patagonia Pharmaceuticals, LLC
Ichthyosis
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
OBJECTIVES: I. Compare the safety and efficacy of monolaurin cream versus a placebo vehicle cream in suppressing the signs of nonbullous congenital ichthyosiform erythroderma. II.
- Trial name
- NCT00004690
- Testing
- monolaurin cream
- Volunteers
- 90 people
- Sponsor
- Cellegy Pharmaceuticals
Ichthyosis, Lamellar
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
Lamellar ichthyosis is a congenital disease of the skin with a generalized scaling. The primary activity of liarozole is considered to be the inhibition of the degradation of a substance called retinoic acid, which is the…
- Trial name
- NCT00282724
- Testing
- Liarozole
- Where
- 16 sites in Belgium, Canada and 7 more
- Volunteers
- 98 people
- Sponsor
- Stiefel, a GSK Company
Sjogren-Larsson Syndrome
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
- Trial name
- NCT03445650
- Testing
- ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Sjögren-Larsson Syndrome
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered…
- Trial name
- NCT02402309
- Testing
- Active topical NS2 1% dermatologic cream
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Lamellar Ichthyosis
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with…
- Trial name
- NCT03738800
- Testing
- CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle
- Where
- 36 sites in United States, Australia and 7 more
- Volunteers
- 65 people
- Sponsor
- Mayne Pharma International Pty Ltd
Netherton Syndrome
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult…
- Trial name
- NCT06539507
- Testing
- BCX17725
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Netherton Syndrome
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
- Trial name
- NCT05521438
- Testing
- QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Quoin Pharmaceuticals
Netherton Syndrome
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body…
- Trial name
- NCT07538583
- Testing
- QRX003
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Quoin Pharmaceuticals
Ichthyosis
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
This is a randomized, double-blind and vehicle-controlled Phase III study to evaluate the safety and efficacy of topical TMB-001 0.05% ointment for the treatment of congenital ichthyosis (CI) in subjects with either the RXLI or…
- Trial name
- ASCEND (NCT05295732)
- Testing
- TMB-001, Matching Vehicle
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 153 people
- Sponsor
- LEO Pharma
Netherton Syndrome
Natural History of Netherton Syndrome
The goal of this non-interventional study (NIS) is to collect real-world data to describe the natural history of Netherton Syndrome (NS).
- Trial name
- NCT05902663
- Where
- 4 sites in United States, Italy
- Volunteers
- 4 people
- Sponsor
- Boehringer Ingelheim
Netherton Syndrome
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
- Trial name
- NCT05789056
- Testing
- QRX003, 4% Lotion
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Quoin Pharmaceuticals
Netherton Syndrome
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
The goal of this clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (including up to the entire body [except the scalp]) works to treat the…
- Trial name
- NCT06953466
- Testing
- QRX003, 4% Lotion
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Quoin Pharmaceuticals
Ichthyosis
Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the Treatment of Ichthyosis
28 Day Survey study in patients with Ichthyosis
- Trial name
- NCT07783165
- Testing
- Doublebase Once
- Volunteers
- 100 people
- Sponsor
- Dermal Laboratories Ltd